A Phase 2/3 interventional study of Masitinib (4.5) and Riluzole in Amyotrophic Lateral Sclerosis (ALS), sponsored by AB Science. Completed at 1 site in Spain. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-09-29.
Sponsored by AB Science · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain — 11 open to participants now, 16 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · Spain.
Among the 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain, this one is the 13th largest by enrollment of the 51 interventional ones that give a count, is one of 2 that started in 2013, is one of 2 in phase 2/3, and was the 15th registered.
980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →11 of the 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Spain, Belgium, Canada and 2 more countries
Ages 18–80
Eli Lilly and Company · Sites in Spain, Belgium, Canada and 2 more countries
Ages 18–80
Prilenia · Sites in Spain, United States, Belgium and 10 more countries
Ages 18–80
PhenoNet, Inc. · Sites in Spain, United States, Czechia and 3 more countries
Ages 18–75
Biogipuzkoa Health Research Institute · Sites in Spain
Ages 18–75
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 19 · Phase 3 24
First in 2007; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 394 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 227 across the 51 interventional studies, 60 across the 5 observational. Of the 37 that completed or were terminated, 20 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 56 have an industry lead sponsor. The 10 most frequent:
AB Science is the lead sponsor of 39 studies on the registry; 5 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
AB Science has 3 studies filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
4 of the studies in Amyotrophic Lateral Sclerosis with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04856982Phase 3BiogenStudy to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | 2027-08-07 |
| NCT07414212Biogipuzkoa Health Research InstituteEvaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosis (ALS) | 2026-11-25 |
| NCT07142291PhenoNet, Inc.PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS | 2027-03 |
| NCT07100119Eli Lilly and CompanyA Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis | 2027-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective is to compare the efficacy and safety of masitinib in combination with riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS).
Masitinib is novel tyrosine kinase inhibitor that targets microglia and mast cells through inhibiting a limited number of kinases. Masitinib blocks microglia proliferation and activation, and mast cell-mediated degranulation, the release of cytotoxic substances that might further damage the motor nerves.
There are two distinct populations of ALS patients: population of "Normal progressors" and population of "Faster progressors". Targeted population for primary analysis is population of "Normal progressors".
"Normal progressors" are ALS patients whose progression of ALSFRS-R score before randomization is less than 1.1 point per month.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Main inclusion criteria:
Exclusion Criteria:
masitinib 3 mg/kg/day + riluzole
Drug: Riluzole · Drug: Masitinib (3.0)
masitinib 4.5 mg/kg/day (2) + riluzole
Drug: Masitinib (4.5) · Drug: Riluzole
Matched placebo
Drug: Riluzole · Drug: Placebo
4.5 mg/kg/day
Also known as: AB1010
Also known as: Rilutek
Also known as: Placebo Oral Tablet
3 mg/kg/day
Also known as: AB1010
Change in Amyotrophic Lateral Sclerosis functional rating scale (ALSFRS)-Revised
The amyotrophic lateral sclerosis functional rating scale (ALSFRS), which is a Validated instrument that assesses the functional status and the disease progression in patients with amyotrophic lateral sclerosis (ALS)
Time frame: From baseline to week 48
Change of Forced Vital Capacity (FVC)
Forced vital capacity (FVC) measures the volume of air expelled from the lungs during a quick, forceful breath.
Time frame: From baseline to week 48
Progression Free Survival
Progression Free Survival is defined as the time from the randomization date until the earliest date for a decline of more than 9-points in ALSFRS-R score
Time frame: Time from the randomization date until the earliest date for a decline of more than 9-points in ALSFRS-R score, asssesd over a maximum of 60 months
Overall Survival
Overall survival is defined as time in months from the randomization date to the date of death due to any cause.
Time frame: Time from the randomization date until death, asssesd over a maximum of 60 months
The record gives a start of Apr 2013, a primary completion of Dec 2016 and a completion of Mar 2018. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Masitinib
Amyotrophic Lateral Sclerosis →